D.E. Shaw & Co
LBRX

D.E. Shaw & Co’s LB Pharmaceuticals LBRX Stock Holding History

D.E. Shaw & Co’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$439K Buy
+13,518
New +$397K ﹤0.01% 4242

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

D.E. Shaw & Co's LBRX Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 13,518 shares worth $439K. The stake represents ﹤0.01% of the portfolio and ranks #4242 among its holdings.

115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • D.E. Shaw & Co held 13,518 shares of LB Pharmaceuticals worth $439K as of Q2 2026.
  • LB Pharmaceuticals was a new D.E. Shaw & Co position in Q2 2026.
  • LB Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4242 holding.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.